Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00710333 · ClinicalTrials.gov registry record · Phase 1
Safety of Juvista When Administered Following Excision of Ear Lobe Keloids
A Phase 1 study of Keloid, sponsored by Renovo.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00710333: Completed Phase 1 study of Keloid, sponsored by Renovo.
NCT00710333 is a Phase 1 study of Keloid that has completed, run by Renovo. The registered enrollment target is 10 participants, below the 2,143-participant average among 8 other Keloid trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00710333, a Phase 1 study of Keloid, has completed, sponsored by Renovo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will assess the safety and efficacy of 500ng Juvista per linear cm of wound margin administered by intradermal injection following the excision of keloid scars on the ear lobe. Ear lobe keloids commonly occur after ear piercing and can be particularly distressing for patients as they are very difficult to conceal and are usually bilateral. As the recurrence rate and growth rate of keloids can vary significantly between individuals, trial subjects will have bilateral ear lobe keloids and will act as their own control. One ear lobe will be treated with Juvista following keloid excision and one with placebo.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Avotermin
Study Locations (1)
Missouri
- Body Aesthetic Plastic Surgery and Skincare Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
What the finished NCT00710333 record still lists
NCT00710333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 2,143-participant average among 8 other Keloid trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Keloid appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00710333 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT00710333 about?
NCT00710333 is a clinical study titled "Safety of Juvista When Administered Following Excision of Ear Lobe Keloids". This trial will assess the safety and efficacy of 500ng Juvista per linear cm of wound margin administered by intradermal injection following the excision of keloid scars on the ear lobe. Ear lobe keloids commonly occur after ear piercing and can be particularly distressing for patients as they are ...
What is the current status of trial NCT00710333?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-07. Estimated completion is 2009-12.
What conditions does trial NCT00710333 study?
This clinical trial studies the following conditions: Keloid.
What interventions are being tested in trial NCT00710333?
The interventions under investigation include: placebo (DRUG), Avotermin (DRUG).
Who is sponsoring clinical trial NCT00710333?
This trial is sponsored by Renovo, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00710333 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keloid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00710333's enrollment target sits among peer trials
10 6th of 8 higher than 1 of 8 other Keloid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Keloid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy
RECRUITING · Phase 2
-
Radiotherapy for Keloids
RECRUITING · NA
-
Genetic Analysis of Keloids
RECRUITING
-
Web Based Investigation of Natural History of Keloid Disorder, an Online Survey
RECRUITING
-
RAPA-Keloid Study of Keloid Regression
COMPLETED · Early Phase 1
-
Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia